Establishment and application of clinical pharmaceutical pathway of anti-infective treatment for high-risk populations of antibiotic-associated encephalopathy
- VernacularTitle:抗菌药物相关性脑病高风险人群抗感染治疗临床药学路径的建立与应用
- Author:
Chunhui DU
1
;
Yongli WAN
2
;
Xiaojiao YANG
1
;
Jin ZHOU
1
;
Jianbo WANG
1
;
Zhenyu ZHAO
1
Author Information
1. Dept. of Pharmacy，Tianjin Medical University Chu Hsien-I Memorial Hospital/Tianjin Institute of Endocrinology/NHC Key Laboratory of Hormones and Development/Tianjin Key Laboratory of Metabolic Diseases，Tianjin 300134，China
2. Dept. of Critical Care Medicine，Tianjin Medical University Chu Hsien-I Memorial Hospital/Tianjin Institute of Endocrinology/NHC Key Laboratory of Hormones and Development/Tianjin Key Laboratory of Metabolic Diseases，Tianjin 300134，China
- Publication Type:Journal Article
- Keywords:
antibiotic-associated encephalopathy;
clinical pharmaceutical pathway;
anti-infection;
neurotoxicity;
personalized
- From:
China Pharmacy
2024;35(21):2690-2696
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish a clinical pharmaceutical pathway of anti-infective therapy for high-risk populations of antibiotic-associated encephalopathy （AAE）， and analyze its application effects. METHODS Clinical pharmacists developed the “AAE High-Risk Population Screening Form” and “Antibiotic AAE Risk Comparison Form” based on literature and expert opinions， and established the “Clinical Pharmaceutical Pathway of Anti-infective Treatment for AAE High-Risk Population” in our hospital. A prospective， non-randomized controlled study was conducted from May 2023 to April 2024， including 50 cases in the observation group and 50 cases in the control group among patients with pulmonary infections admitted to the Dept. of Internal Medicine in our hospital. The observation group was involved in the development of an anti-infective treatment following the clinical pharmaceutical pathway by clinical pharmacists， while the control group received routine anti-infective treatment by clinical physicians. The occurrence of AAE， the rational antibiotic drug use， and the effectiveness of initial anti-infective treatment in the two groups were observed， and the intervention measures and outcomes of AAE cases were summarized. RESULTS The anti-infective treatment clinical pharmaceutical pathway for AAE high-risk population was preliminarily established in our hospital. The analysis of the application effects showed that there was 1 case of AAE in the observation group and 8 cases in the control group， with a significantly lower incidence of AAE in the observation group than in the control group； the rational antibiotic drug use and the effectiveness of initial anti-infective treatment in the observation group were both significantly superior to those in the control group （P＜0.05）. Drug withdrawal and dressing change were the preferred effective intervention measures for AAE， and encephalopathy treatment drugs could be used as auxiliary measures for symptom relief. Timely and effective intervention was conducive to rapid symptom relief， with a total improvement rate of AAE of 88.89%. CONCLUSIONS The anti-infective treatment clinical pharmaceutical pathway for AAE high-risk population can effectively prevent the occurrence of AAE as well as contribute to promoting rational drug use and the effectiveness of initial anti-infection plans and strengthening treatment outcomes.
